enGene Holdings Inc.

ENGN
$1.78 (+ $0.02 + 1.14%)
Last updated: 2026-07-29 20:35 UTC
ENGN Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINCA29286M1059
Market Price1.78
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-2.29
Market Cap$631.3M
Book Value3.22
Price to Book2.923
BetaN/A
52w High11.14
52w Low2.65
Next Earnings DateN/A

enGene Holdings Inc. trades under ticker ENGN on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN CA29286M1059. Also searched as enGene Holdings.

Related researchENGN stock priceENGN share priceenGene Holdings stockenGene Holdings share price
About the Company
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
Price History